JANX Janux Therapeutics Inc: Enterprise Value-to-Revenue Multiple

Public company logo of januxrx.com (JANX)

The price-to-sales ratio dynamics for Janux Therapeutics (JANX) correlate with expectations for the commercialization of TRACTr T-cell therapies. The potential for global dominance following molecule approval is currently superseded by a phase of costly clinical trials where expenses are growing linearly. The value of -12699.01 serves as a current metric that helps investors filter out market noise and assess the risk of overpaying for the asset.

Company Value to Revenue: Janux Therapeutics Inc (JANX) for 11/23/2025 - 11/20/2026

januxrx.com - analytical breakdowns and key metrics (JANX)

- share price and consensus valuation forecast:
- money and cash flow information:
Initial company analysis:Janux Therapeutics JANX
Product sample of Janux Therapeutics

EV/Sales measures the total value of a business, including debt, relative to the volume of revenue generated. This multiple allows an investor to assess the efficiency of revenue capitalization regardless of the financing structure. By analyzing the EV/Sales value on the GURU.Markets platform, one can identify whether an asset is overvalued or undervalued. For Janux Therapeutics (JANX), the stability of this metric confirms market confidence in its operational resilience, which is further supported by robust diversification of biomedical component supplies for clinical trials.

Competitor analysis for Janux Therapeutics

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Arcus Bio (RCUS)|Company Value to Revenue ZYME|TNGX - Enterprise Value-to-Sales Ratio|Company Value to Revenue IOVA (Iovance)|Enterprise Value-to-Revenue Coefficient IMTX|EV/Sales Multiple XNCR (Xencor)|Business Value to Revenue CMPX|replimune.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Lyell Pharma|Innate Pharma S.A. (IPHA) - Enterprise Value-to-Revenue Ratio|Pyxis Oncology Inc. - Business Value to Revenue|CGEN (Compugen Limited) - EV/Sales Multiple|EV/Sales Multiple IO Biotech Inc|Enterprise Value-to-Revenue Ratio Sutro Biopharma (STRO)|INKT: Enterprise Value to Sales Volume|Werewolf Therapeutics, Inc. - Company Value to Revenue|Immix (IMMX) - Enterprise Value-to-Revenue Multiple|ALX Oncology Holdings Inc. - EV/Sales Multiple|CUE - EV/Sales Multiple|PDSB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP